Rituximab ITP Aiha denied as non-formulary by Humana?

Humana's specific coverage criteria for rituximab itp aiha are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Rituximab (ITP/AIHA) as Non-Formulary

Humana's formulary — the list of drugs the plan covers — may not include rituximab for the ITP or AIHA diagnosis submitted, either because the drug is excluded entirely for that indication or because the specific J-code or NDC submitted did not match the formulary entry. Non-formulary denials are common for specialty biologics and are among the most frequently overturned through the formulary-exception process, particularly when there is no covered formulary alternative that is clinically appropriate for your situation.

## Why This Denial Is Appealable

Federal law requires health plans to have an exceptions process for non-formulary drugs when a formulary alternative is contraindicated, clinically inappropriate, or when you have already tried and failed a covered alternative. If your hematologist can document that no formulary alternative is appropriate for your specific case — or that you have already trialed covered alternatives without adequate response — you are entitled to a formulary exception that would authorize coverage at a standard tier.

## Federal Appeal Framework

• Formulary exception request: File simultaneously with your internal appeal. Under ACA §2719 and ERISA §503, Humana must review exceptions requests and provide a timely written decision.
• Internal appeal: If the exception is denied, escalate to a full internal appeal. Humana must provide a full-and-fair review with clinical expertise.
• External review: A denial upheld after internal review may be submitted to an IRO within the approximately four-month federal window. IROs assess whether the plan's formulary exclusion is consistent with accepted medical standards given your individual clinical needs.
• Expedited processing: Available if treatment delay poses serious health risk.

## Documentation to Gather

• Formulary alternative review: Obtain Humana's current formulary and identify every listed alternative for ITP or AIHA. For each alternative, document either that it was trialed and failed or that the prescriber has a clinical reason it is inappropriate for this patient.
• Prescriber letter: Should explain why rituximab is required and why formulary alternatives are not adequate substitutes for this patient's specific clinical situation.
• Prior-treatment history: Dated records of all prior therapies including any covered formulary agents already tried.
• Diagnosis and severity documentation: Hematology notes and lab trends establishing the clinical need for treatment.

## Criteria-Mapping Structure

Build a table listing each formulary alternative on the left, with a corresponding explanation on the right of why it is not a clinically appropriate substitute (trialed and failed, contraindicated per the chart, or otherwise inappropriate as documented by the prescriber). Attach Humana's current formulary page as an exhibit. A structured formulary-exception submission is far more likely to succeed than a narrative letter alone.